Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

AmerisourceBergen
Pharmalot

AmerisourceBergen will eliminate 15 percent of workers at a troubled compounding unit

By Ed Silverman

Chemotherapy infusion
Pharmalot

Trump proposal to shift Part B drugs to Part D would hurt most beneficiaries, analysis says

By Ed Silverman

Pharmalot

Allergan and a Mohawk tribe ask the Supreme Court to review their controversial patent deal

By Ed Silverman

Pharmalot

Pharmalittle: Walmart leaves CVS networks over pricing; EMA to lose 25 percent of its staff due to relocation

By Ed Silverman

Peter Welch
Pharmalot

Lawmakers want feds to look at how a Bristol-Celgene deal affects prices and competition

By Ed Silverman

VA veterans affairs building
Pharmalot

Medicare Part D could have saved $14.4 billion in 2016 by negotiating as the VA did

By Ed Silverman

Novartis International pharmaceutical
Pharmalot

Novartis battles with the Dutch health minister for raising the price of a cancer drug

By Ed Silverman

Pharmalot

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: ‘Netflix’ model for hep C drugs proceeds; J&J hikes drug prices

By Elizabeth Cooney

Hep C San Fran
Pharmalot

Louisiana proceeds with plans for a ‘Netflix’ subscription model to buy hepatitis C drugs

By Ed Silverman

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

Pharmalot

Pharmalittle: Biologic makers use scare tactics to ward off biosimilar use; insulin prices are raised

By Ed Silverman

Pharmalot

Pharmalittle: Allergan CEO says ‘social contract’ intact; medical marketing skyrockets to $30 billion

By Elizabeth Cooney

Brent Saunders
Pharma

Allergan CEO: We stuck to the spirit of our social contract with recent price hikes

By Ed Silverman and Matthew Herper

Drug Prices
Pharmalot

California governor moves to bolster negotiating power for lower drug prices

By Ed Silverman

Pharma TV Ad
Pharmalot

Medical marketing exploded over the past two decades, raising questions about industry influence

By Ed Silverman

Pharmalot

Pharmalittle: Existing drugs driving higher prices; Baselga lands at AstraZeneca

By Elizabeth Cooney

Pharmacy Benefit Managers
Pharmalot

Price hikes on existing medicines account for the lion’s share of higher drug costs

By Ed Silverman

Pharmacy shelves
Pharmalot

Vermont projects modest savings from a plan to import drugs from Canada

By Ed Silverman

Pharmalot

Pharmalittle: Lilly makes a huge bet on Loxo; what about the Michaels?

By Elizabeth Cooney and Ed Silverman

Pharmacy shelves
Pharmalot

Generic drug maker formed by hospitals attracts a dozen more health systems

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Azar says price hikes are lower this year; JP Morgan health confab is dreaded by many

By Ed Silverman

Pills price rebate
Pharmalot

Payers expect drug prices to rise 3 percent to 5 percent annually over the next three years

By Ed Silverman

Pharmalot

Pharmalittle: Bristol-Myers to pay $74 billion for Celgene; Trump expects drug prices to fall

By Ed Silverman

California State flag
Pharmalot

California reports show changes in drug spending as two companies sue over disclosure

By Ed Silverman

Pharmalot

Gilead tussles with the Malaysian government over licensing for its hepatitis C treatment

By Ed Silverman

Pharmalot

Pharmalittle: A new year brings rising drug prices; Democratic presidential contenders target drug prices

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy